

Remarks/Arguments


The patent office Notice to Comply mailed April 2, 2008 points out that reference to the amino sequence "LPXTG" on page 19 fails to provide a sequence identifier. In reviewing the specification for related sequences lacking an identifier, "LPXTG" was found in additional places and the sequence "LPXTGVI" was also identified.

The present amendment to the specification provides sequence identifiers for "LPXTG" and "LPXTGVI", corrects a typographically error on page 2, line 23 ("cell well" was corrected to read "cell wall") and provides a corrected sequence listing. The corrected sequence listing provides for "LPXTG" and "LPXTGVI"; indicates that SEQ ID NO: 1 is ORF0657nI with amino terminus methionine (see Table 1 of the application on page 8), rather than ORF0657n with amino terminus methionine; and provides an updated general information section.

The contents of the enclosed paper and computer readable form of the Sequence Listing are the same. As noted above, the changes to the Sequence Listing provides sequences described in the specification, corrects an obvious error in the description of a sequence, and provides an updated general information section. Thus, no new matter was introduced into the Sequence Listing.

Please charge deposit account 13-2755 for fees due in connection with this response. If any time extensions are needed for the timely filing of the present response, applicants petition for such extensions and authorize the charging of deposit account 13-2755 for the appropriate fees.

Respectfully submitted,

By 
Sheldon O. Heber
Reg. No. 38,179
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000
Rahway, NJ 07065-0907
(732) 594-1958